Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences, Inc. entered into a new senior secured credit agreement on April 1, 2026, providing an initial term loan of $400,000,000, a committed delayed draw term facility of up to $300,000,000, and an uncommitted incremental facility of up to $500,000,000.
The initial term loan funded at closing and matures in April 2031, while the delayed draw facility is available through August 2027 and may be used only for Permitted Acquisitions. Loans bear interest at a Term SOFR or Base Rate option plus margins of 5.00% or 4.00%, respectively, for the term and delayed draw loans.
The facilities are guaranteed by certain subsidiaries and secured by substantially all tangible and intangible personal property. The agreement includes customary covenants and events of default, and requires minimum qualified cash of $50 million at each fiscal quarter-end. The company used proceeds from the initial term loan to fully repay and terminate its January 18, 2023 credit agreement, including related guarantees and liens.
Power Luke Thomas reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. executive Luke Thomas Power received an equity grant in the form of restricted stock units. The award covers 63,971 shares of Common Stock, granted at no cash cost to him as compensation. According to the footnote, these restricted stock units will vest in line with the terms of the applicable grant agreement. Following this grant, he directly holds 163,542 shares of Common Stock.
Denton John Russel reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. officer John Russel Denton received a grant of 63,971 shares of Common Stock on March 6, 2026, reported as restricted stock units that will vest under the applicable grant agreement. Following this grant, he holds 187,562 shares directly and 9,184 shares indirectly through a trust.
Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. President David Baxley Spetzler received an award of 83,162 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and will vest in accordance with the applicable grant agreement. Following this compensation-related grant, he holds 543,939 shares of Common Stock directly.
Brille Brian J reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director and officer Brian J. Brille received a grant of 83,162 shares of Common Stock in the form of restricted stock units on March 6, 2026, at no cash cost, as compensation that will vest under the applicable grant agreement.
Following this grant, he directly holds 244,290 Common shares. In addition, a family trust holds 500,000 Common shares, with Brille reporting the position indirectly and disclaiming beneficial ownership except for his pecuniary interest.
Caris Life Sciences director and officer David D. Halbert reported an acquisition of 320,112 shares of Common Stock on March 6, 2026 as a restricted stock unit award that vests under its grant agreement. These shares were received at a stated price of $0.00 per share, bringing his directly held Common Stock to 2,615,245 shares after the transaction.
The filing also shows 121,025,002 shares of Common Stock held indirectly through several affiliated entities, including Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC. Halbert has voting and investment power over these entity holdings but disclaims beneficial ownership beyond his pecuniary interest.
Caris Life Sciences, Inc. describes a precision oncology business built on comprehensive molecular profiling and artificial intelligence. The company focuses on tissue- and blood-based sequencing to guide cancer diagnosis, therapy selection, minimal residual disease tracking, and early detection.
Caris reports sequencing over 1,000,000 oncology cases as of December 31, 2025 and serving more than 6,000 ordering physicians. Its MI Profile tissue platform, Caris Assure blood platform, and planned whole genome solutions, including the Caris Detect early detection assay expected in 2026, generate large multi-modal datasets used for clinical care, biopharma partnerships, and internal drug discovery.
The company highlights FDA-approved MI Cancer Seek as a WES/WTS companion diagnostic, growing Medicare and commercial coverage for Caris Assure, extensive intellectual property, and a global research network. It also notes a substantial biopharma services and data-licensing business built on its clinico-genomic and imaging datasets.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Lloyd Minor reported receiving 2,492 shares of common stock on February 26, 2026. These shares were issued as equity in lieu of cash compensation for his 2025 board retainer fees, based on a ten-day average trading price. Following this award, his direct holdings increased to 18,621 shares of common stock.
Caris Life Sciences director Jeff L. Vacirca received a stock grant instead of cash board fees. On February 26, 2026, he acquired 2,492 shares of common stock at $20.06 per share as compensation for his 2025 board retainer, bringing his direct holdings to 18,621 shares.
Caris Life Sciences director David Paul Fredrickson acquired 2,492 shares of common stock as compensation. The shares were issued on February 26, 2026 in lieu of cash payment for his 2025 board retainer fees, valued at $20.06 per share.
After this stock award, his directly held stake increased to 18,621 common shares. The number of shares granted was calculated by dividing the cash retainer earned by the 10-day average volume-weighted average price per share through February 25, 2026.